Visara, Inc. | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

41,166 results for “Visara, Inc.”

NovaBridge to Report First Half 2026 Results and Corporate Update on August 20

NovaBridge Subsidiary Visara Assigns VIS-101 License to Everest Medicines for Asian Markets

NovaBridge's VIS-101 Shows Promising Phase 2a Results in Wet AMD with Potential Best-in-Class Durability

I-Mab Announces Strategic Transformation to NovaBridge Biosciences with Hong Kong IPO Plans and VIS-101 Acquisition

Virios Therapeutics and Wex Pharmaceuticals Merge to Form Dogwood Therapeutics, Advancing Novel Pain and Viral Therapies

LYMPHIR and Pembrolizumab Combination Shows Promise in Recurrent Solid Tumors

Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Highlights

IDEAYA Biosciences, Inc. (IDYA) BCG Matrix Analysis 2024

Immix Biopharma's NXC-201 Shows Promise as Outpatient CAR-T Therapy in Amyloidosis and Multiple Myeloma

Acelyrin Inc. Faces Market Volatility Amidst Clinical Trial Updates

Page 1 of 2195